Global Summit on Improving the Bioavailability of Medicines 2022: two-day online program – May 16-17, 2022

DUBLIN, April 1, 2022 /PRNewswire/ — The “Global Summit on Improving Drug Bioavailability 2022” conference has been added to from offer.

Are you responsible for improving drug performance, bioavailability and patient adherence? Would you like to discover new strategies to reduce dosage, costs and reduce time to market of products?

Check out the 2022 Global Summit on Improving Drug Bioavailability program agenda and walk away with 2+ years of novel drug formulation and bioavailability improvement strategies. Learn directly from 30+ senior drug bioavailability pioneers and network with 120+ senior drug development innovators next May in Philadelphia, PA.

The 2022 2-day program features the latest in industry formulation and delivery technologies to improve solubility and maximize bioavailability. The 2022 Summit will share cutting-edge research on the development, characterization and manufacturing of formulations spanning multiple modalities.

  • Precision Medicine and Healthcare Delivery
  • Rational formulation design for poorly soluble compounds
  • In-vivo – in-vitro correlation
  • Solution behavior of amorphous solid dispersions
  • Nanosuspension to improve bioavailability
  • Early Formulation Screening in Drug Discovery
  • 3D printing for biopharma
  • Improving patient adherence via drug administration
  • Innovative strategies around drug/device combinations

2021 speakers included:

Manish Guptadoctorate
Senior Director, Pharmaceutical Development – Sterile

Dedong Wudoctorate
Senior Scientist, Solid State
Astra Zeneca

Arijit Chakravartydoctorate
Chief executive officer
Fractal therapy

Rick Panicuccidoctorate
Senior Vice President, CMC
Therapeutic QED

Saji Vijayandoctorate
Vice President – R&D Strategy
Endo Pharmaceuticals

Sune Andersondoctorate
Senior Scientist, Spray Drying
Johnson & Johnson

Susan Rosenbaum
Founder, CEO
Laurent Science

stephen tindaldoctorate
Director, Science and Technology
Catalent Pharmaceutical Solutions

Melanie Marotadoctorate
Associate Principal Investigator, Pharmaceutical Sciences
Merck & Co.

Eric Munsondoctorate
Patrick DeLuca Endowed Professor of Pharmaceutical Technology, Department of Pharmaceutical Sciences
Purdue University

Di Wudoctorate
Senior Scientist, Formulation Development
Merck & Co.

Stephen Sterndoctorate
Director of Research and Development, Head of the Pharmacology and Toxicology Section
Nanotechnology Characterization Laboratory

Dabing Chen, Ph.D.
Senior Principal Scientist
Boehringer Ingelheim

Xin Liudoctorate
Associate Director of Pharmaceutical Product Development

Christopher Nuboldt
Principal Investigator

Sudhakar Garaddoctorate
Global Head of Chemical and Pharmaceutical Profiling

For more information about this conference, visit

Media Contact:

Research and Markets
Laura Woodsenior
[email protected]

For EST office hours, call +1-917-300-0470
For USA/CAN call toll free +1-800-526-8630
For GMT office hours call +353-1-416-8900

US Fax: 646-607-1907
Fax (outside the US): +353-1-481-1716

Quote Show original content:—may-16-17-2022-301515643.html

SOURCE Research and Markets

Karen O. Fielding